



For Immediate Release

Symic Bio to Present at the 22nd Annual BIO Europe Conference

SAN FRANCISCO, Nov. 2, 2016 – Symic Bio, a clinical-stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the 22nd Annual BIO Europe Conference in Cologne. The presentation will take place within the autoimmune/inflammation track.

Conference details are as follows:

Date: Tuesday, Nov. 8, 2016

Time: 3:00 p.m. CET

Location: Rheinsaal 4, Level 2, Koelnmesse - Congress Center North, Cologne, Germany

About Symic Bio

Symic Bio is a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, one for the treatment of critical limb ischemia (SB-030) and one directed at disease-modification in the treatment of osteoarthritis (SB-061). In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

###

Investor Contacts

Lisa Burns or Bill Slattery, Jr.
Burns McClellan, Inc.
(212) 213-0006
ir@symic.bio

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(212) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com